EE200100697A - Farmatseutiline kompleks - Google Patents

Farmatseutiline kompleks

Info

Publication number
EE200100697A
EE200100697A EEP200100697A EEP200100697A EE200100697A EE 200100697 A EE200100697 A EE 200100697A EE P200100697 A EEP200100697 A EE P200100697A EE P200100697 A EEP200100697 A EE P200100697A EE 200100697 A EE200100697 A EE 200100697A
Authority
EE
Estonia
Prior art keywords
pharmaceutical complex
pharmaceutical
complex
Prior art date
Application number
EEP200100697A
Other languages
English (en)
Estonian (et)
Inventor
Billotte Anne
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of EE200100697A publication Critical patent/EE200100697A/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200100697A 1999-06-29 2000-06-02 Farmatseutiline kompleks EE200100697A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex
PCT/IB2000/000746 WO2001000243A1 (en) 1999-06-29 2000-06-02 Pharmaceutical complex

Publications (1)

Publication Number Publication Date
EE200100697A true EE200100697A (et) 2003-02-17

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100697A EE200100697A (et) 1999-06-29 2000-06-02 Farmatseutiline kompleks

Country Status (44)

Country Link
US (2) US6713461B1 (bg)
EP (1) EP1189640B1 (bg)
JP (2) JP4454900B2 (bg)
KR (1) KR20020015067A (bg)
CN (1) CN1198654C (bg)
AP (1) AP2001002369A0 (bg)
AR (1) AR033337A1 (bg)
AT (1) ATE290884T1 (bg)
AU (1) AU770169B2 (bg)
BG (1) BG106151A (bg)
BR (1) BR0011845A (bg)
CA (1) CA2376847C (bg)
CO (1) CO5170494A1 (bg)
CZ (1) CZ20014572A3 (bg)
DE (1) DE60018744T2 (bg)
DZ (1) DZ3320A1 (bg)
EA (1) EA003908B1 (bg)
EC (1) ECSP003551A (bg)
EE (1) EE200100697A (bg)
ES (1) ES2235879T3 (bg)
GB (1) GB9915231D0 (bg)
GE (1) GEP20043377B (bg)
GT (1) GT200000102A (bg)
HR (1) HRP20010951A2 (bg)
HU (1) HUP0201629A3 (bg)
IL (1) IL146341A0 (bg)
IS (1) IS6163A (bg)
MA (1) MA26801A1 (bg)
MX (1) MXPA01013274A (bg)
NO (1) NO20016430L (bg)
NZ (1) NZ515235A (bg)
OA (1) OA11964A (bg)
PA (1) PA8496801A1 (bg)
PE (1) PE20010346A1 (bg)
PL (1) PL352902A1 (bg)
SK (1) SK18932001A3 (bg)
SV (1) SV2002000112A (bg)
TN (1) TNSN00142A1 (bg)
TR (1) TR200103827T2 (bg)
UA (1) UA66932C2 (bg)
UY (1) UY26224A1 (bg)
WO (1) WO2001000243A1 (bg)
YU (1) YU87501A (bg)
ZA (1) ZA200110454B (bg)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
ES2322953T3 (es) * 2002-08-20 2009-07-02 Bristol-Myers Squibb Company Formulacion del complejo de aripiprazol y procedimiento.
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (en) * 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
US20190224171A1 (en) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Liquid rizatriptan compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
HU211648A9 (en) 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
CA2091562C (en) 1990-10-15 2001-03-27 John Eugene Macor Indole derivatives useful in psychotherapeutics
WO1994020091A1 (en) 1993-03-05 1994-09-15 Hexal Pharma Gmbh Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation
KR100357839B1 (ko) 1994-03-07 2003-08-02 더 다우 케미칼 캄파니 생체활성및/또는표적화된덴드리머콘쥬게이트
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
CN1230123A (zh) 1996-07-11 1999-09-29 荷兰发马克有限公司 含碱性药物的酸加成盐的药物组合物
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
CA2292673C (en) 1997-07-03 2003-04-22 Pfizer Inc. Pharmaceutical compositions containing eletriptan hemisulphate
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
EP1189640A1 (en) 2002-03-27
MXPA01013274A (es) 2002-06-04
IL146341A0 (en) 2002-07-25
NO20016430D0 (no) 2001-12-28
HUP0201629A3 (en) 2003-11-28
JP2006257091A (ja) 2006-09-28
CN1198654C (zh) 2005-04-27
SK18932001A3 (sk) 2002-09-10
AP2001002369A0 (en) 2001-12-31
TNSN00142A1 (fr) 2005-11-10
MA26801A1 (fr) 2004-12-20
GB9915231D0 (en) 1999-09-01
CO5170494A1 (es) 2002-06-27
GEP20043377B (en) 2004-04-13
ECSP003551A (es) 2002-01-25
PE20010346A1 (es) 2001-03-26
EP1189640B1 (en) 2005-03-16
UA66932C2 (en) 2004-06-15
CN1359303A (zh) 2002-07-17
EA200101106A1 (ru) 2002-06-27
US6713461B1 (en) 2004-03-30
CA2376847A1 (en) 2001-01-04
AR033337A1 (es) 2003-12-17
JP2003503364A (ja) 2003-01-28
CZ20014572A3 (cs) 2002-08-14
BR0011845A (pt) 2002-03-05
ES2235879T3 (es) 2005-07-16
AU770169B2 (en) 2004-02-12
BG106151A (bg) 2002-05-31
GT200000102A (es) 2001-12-14
TR200103827T2 (tr) 2002-05-21
PA8496801A1 (es) 2002-02-21
OA11964A (en) 2006-04-17
CA2376847C (en) 2007-09-25
NZ515235A (en) 2003-08-29
JP4454900B2 (ja) 2010-04-21
SV2002000112A (es) 2002-02-05
EA003908B1 (ru) 2003-10-30
IS6163A (is) 2001-11-16
PL352902A1 (en) 2003-09-22
US20040186076A1 (en) 2004-09-23
WO2001000243A1 (en) 2001-01-04
DZ3320A1 (fr) 2001-01-04
ZA200110454B (en) 2002-12-20
ATE290884T1 (de) 2005-04-15
HRP20010951A2 (en) 2005-04-30
AU4774100A (en) 2001-01-31
NO20016430L (no) 2002-02-26
HUP0201629A2 (hu) 2003-03-28
DE60018744D1 (de) 2005-04-21
KR20020015067A (ko) 2002-02-27
YU87501A (sh) 2004-05-12
DE60018744T2 (de) 2006-05-18
UY26224A1 (es) 2001-01-31

Similar Documents

Publication Publication Date Title
NO20015175L (no) Farmasöytisk sammensetning
ATE392890T1 (de) Hydrogel-gesteuerte dosierungsform
DE122007000064I2 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
IS6040A (is) Valdekoxib efnablöndur
DE10084676T1 (de) Einmallanzettvorrichtung
ATA51899A (de) Handstempel
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
DE50001455D1 (de) Blisterverpackung
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
NO20022606L (no) Farmasöytiske kombinasjoner
PT1210085E (pt) Solucoes farmaceuticas de levosimendano
DK1275397T3 (da) Lægemiddel til lokal anvendelse
NO20014926D0 (no) Farmasöytiske forbindelser
FI4488U1 (fi) Farmaseuttinen koostumus
DE10085008T1 (de) Oberflächenbehandlungsdüse
NO20016430L (no) Farmasöytisk kompleks
AR025867A1 (es) Formulacion portasdora farmaceutica
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE59905747D1 (de) Blisterpackung
FR2799574B1 (fr) Contacteur-disjoncteur
ATE269311T1 (de) Benzoylpyridazine
DE10082008D2 (de) Ausbeulgerät
DE50009295D1 (de) Vernetzerfreie zubereitungen
ATE440824T1 (de) Nitro-sulfobenzamide